Security key
810648105
scPharmaceuticals Inc. - Common Stock, par value $0.0001 per share (SCPH)
CUSIP: 810648105
Q2 2020 13F Holders as of 30 Jun 2020
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 17,536,133
- Total 13F value
- $129,064,483
- Share change
- +5,047,553
- SEC-reported price per share
- $7.36
- Number of holders
- 51
- Value change
- +$37,153,425
- Number of buys
- 42
- Number of sells
- 11
- Shares outstanding
- 53,364,241
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2020
Institutions
51
Top holders
10
SCPH full security history
Ownership snapshot
Full 13F holder table
scPharmaceuticals Inc. SEC filings
scPharmaceuticals Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of SCPH - scPharmaceuticals Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
RA CAPITAL MANAGEMENT, L.P.
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
0/15
Latest evidence
31 Mar 2020
13F
Highest disclosed value: $26,041,000
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
RA CAPITAL MANAGEMENT, L.P. has the largest disclosed position value at $26.04M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.
Disclosed position value
Top 5
RA CAPITAL MANAGEMENT, L.P.
$26.04M
ORBIMED ADVISORS LLC
$25.23M
5AM Venture Management, LLC
$24.08M
Ikarian Capital, LLC
$7.94M
VANGUARD GROUP INC
$1.8M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
—
denominator unverified
|
$26,041,000
3,518,998 shares
|
— | 31 Mar 2020 |
| ORBIMED ADVISORS LLC |
13F
Company
|
—
denominator unverified
|
$25,233,000
3,409,865 shares
|
— | 31 Mar 2020 |
| 5AM Venture Management, LLC |
13F
Company
|
—
denominator unverified
|
$24,075,000
3,253,440 shares
|
— | 31 Mar 2020 |
| Ikarian Capital, LLC |
13F
Company
|
—
denominator unverified
|
$7,945,000
1,073,647 shares
|
— | 31 Mar 2020 |
| VANGUARD GROUP INC |
13F
Company
|
—
denominator unverified
|
$1,805,000
243,965 shares
|
— | 31 Mar 2020 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
—
denominator unverified
|
$1,424,000
192,486 shares
|
— | 31 Mar 2020 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2020
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
51
Shares
17,536,133
Rows available
51
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2020 vs Q1 2020 Across Filers
Q1 2020 holders
32
Q2 2020 holders
51
Holder diff
19
| Investor | Q1 2020 Shares | Q2 2020 Shares | Share Diff | Share Chg % | Q1 2020 value | Q2 2020 value | Value change | Value Chg % |
|---|